« Return to News | CROs/Service Providers

Potthoff named president, CEO of Theorem Clinical Research

Wednesday, November 2, 2011 01:13 PM

John Potthoff has stepped down as chief operating officer of CRO INC Research to become president and CEO of Theorem Clinical Research, succeeding James Pusey, who now becomes Theorem’s executive chairman to the board of directors.

Potthoff came to INC when Tanistry, a CNS-focused CRO he founded, was bought by the company. During his time at INC, Potthoff led CNS therapeutics, global business development and clinical development in North America. Prior to founding Tanistry and serving as its president and CEO, Potthoff spent seven years with PPD.

Theorem is the new company formed when publicly-traded Omnicare spun off its CRO holdings, selling them to equity investment firm Nautic Partners in April 2011. Pusey became president and CEO of the Omnicare CRO in 2009, tasked with fixing the ailing division and transitioning it through its spin off and sale. Before that, he had turned around MDS Pharma Services’ late-phase CRO operations, which were then sold to INC. 


Theorem has about 900 employees, and in the last nine months has seen a significant increase in backlog, with the majority of growth in North America and Asia Pacific, as well as in the CRO’s technical services and medical device business units, Pusey said in a release.

--Suz Redfearn

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.